Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.40 |
| ▸ | DRD4 | P21917 | 6/20 | 0.38 |
| ▸ | NAAA | Q02083 | 2/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.35 |
| ▸ | FEN1 | P39748 | 3/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12740338 | 0.97 | SIGMAR1 (0.40) | SIGMAR1TMEM97DRD4NAAAALOX5AP | |
| SCHEMBL12740341 | 0.96 | SIGMAR1 (0.39) | SIGMAR1TMEM97DRD4NAAAALOX5AP | |
| SCHEMBL12740339 | 0.96 | SIGMAR1 (0.39) | SIGMAR1TMEM97DRD4NAAAALOX5AP | |
| SCHEMBL12740340 | 0.96 | SIGMAR1 (0.39) | SIGMAR1TMEM97DRD4NAAAALOX5AP | |
| SCHEMBL14766846 | 0.94 | NAAA (0.38) | SIGMAR1TMEM97DRD4NAAAALOX5AP | |
| SCHEMBL12740336 | 0.92 | SIGMAR1 (0.43) | SIGMAR1TMEM97DRD4NAAAALOX5AP | |
| SCHEMBL14766637 | 0.92 | FFAR1 (0.37) | SIGMAR1DRD4NAAAALOX5APFEN1 | |
| SCHEMBL14766989 | 0.91 | NAAA (0.37) | SIGMAR1DRD4NAAAALOX5APFEN1 | |
| SCHEMBL12740344 | 0.90 | SIGMAR1 (0.39) | SIGMAR1TMEM97DRD4NAAAALOX5AP | |
| SCHEMBL14767003 | 0.90 | PPARD (0.38) | NAAAALOX5APFEN1HTR6FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | SIGMAR1 1690/4885TMEM97 2963/4885DRD4 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.